Bart J. Keulen

Bart J. Keulen

Auto-generated profile, based on publicly available information

Bart J. Keulen

Department of Neurology, Amsterdam UMC, Amsterdam Neuroscience, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2025 in Journal of Neural Engineering
Verified
Journal Article
Open access
BSBart Swinnen
Bart Swinnen
ABArthur W G Buijink
Arthur W G Buijink
MSMariëlle J Stam
Mariëlle J Stam
DHDeborah Hubers
Deborah Hubers
MNMartijn de Neeling
Martijn de Neeling
MBMartijn Beudel
Martijn Beudel
Objective. Local field potential (LFP) recordings using chronically implanted sensing-enabled stimulators are a powerful tool for indexing symptom presence and severity in neurological and neuropsychiatric disorders, and for enhancing our neurophysiological understanding of brain processes. LFPs have gained interest as input signals for closed-loop deep brain stimulation (DBS) and can be used to inform DBS parameter selection. LFP recordings using chronically implanted sensing-enabled stimulators have various implementational challenges. Approach. Here we describe our collective experience using BrainSense (Medtronic®) for clinical and research work. We aim to provide insightful tips and practical advice to empower readers with the knowledge needed to navigate the intricacies of the device and make the most out of its features. Main results. The central issues that apply to several BrainSense features encompass restricted compatibility of stimulation configuration with sensing, differences in electrophysiological signal properties between ‘stimulation OFF’ and ‘stimulation ON at 0.0 mA’, and challenges associated with the internal clock of the neurostimulator. In addition, since recordings are obtained from bipolar and not monopolar channels, spatial certainty regarding the distribution of LFPs around the DBS electrode is limited. Several options exist to synchronize LFP time series with external data streams, but standardization and generalization are lacking. The use of at-home chronic LFP recording is limited by a low temporal and spectral resolution. Regarding at-home LFP snapshots, LFP time series are not stored, parts of the power spectrum are censored when stimulating at high or low frequencies, and the stimulation amplitude is not readily available. Significance. We discussed practical applications, implementation, system limitations, and pitfalls with the aim that sensing can be better applied for clinical practice and research.

29 August 2025 in Annals of Neurology
Verified
Journal Article
Open access
MNMartijn G.J. de Neeling
Martijn G.J. de Neeling
BKBart J. Keulen
Bart J. Keulen
MSMariëlle J. Stam
Mariëlle J. Stam
DHDeborah Hubers
Deborah Hubers
RBRob M.A. de Bie
Rob M.A. de Bie
MBMartijn Beudel
Martijn Beudel
Objective: In Parkinson's disease (PD), the power of beta oscillations (± 13–30 hertz [Hz]) from subthalamic nucleus (STN) local field potentials (LFPs) is associated with motor symptoms. Beta power can be used for adaptive deep brain stimulation (aDBS) algorithms based upon symptom fluctuations. The time course of beta power modulations after levodopa intake at home remains to be described. Methods: Ten‐minute averages of beta peak power were recorded in 33 patients with PD treated with STN‐DBS for a median duration of 134 days during the titration phase. Median beta power after scheduled medication intakes (n = 24,103) and the effects of peak frequency, stun effect, stimulation amplitude, levodopa dose, and preoperative levodopa response were analyzed using cluster‐based permutation testing. Results: Beta power was significantly reduced between 30 and 140 minutes after intake for stimulation amplitudes between 0 and 2.1 mA ( p < 0.01). This response was seen in low (12.7–20.5 Hz) but not high (21.5–30.3 Hz) beta frequencies. Significant clusters were found regardless of stun effect and preoperative levodopa response, during low stimulation amplitudes (< 1 mA), and for 100 and 150 mg but not 50 mg doses. A linear mixed‐effects model for the area under the curve (AUC) levodopa beta response (30–180 min) revealed a dose–response relationship, a stronger negative response in low‐beta compared with high‐beta frequencies, and no significant effect of stimulation amplitude. Interpretation: STN beta power responds to levodopa during low to moderate stimulation amperages, depending on the beta peak frequency and dose, which is informative for aDBS implementation. ANN NEUROL 2025;98:1352–1363

1 May 2026 in Movement Disorders Clinical Practice
Verified
Journal Article
Closed access
DHDeborah Hubers
Deborah Hubers
BKBart J. Keulen
Bart J. Keulen
MBMartijn Beudel
Martijn Beudel

10 March 2026 in Brain Stimulation
Verified
Journal Article
Open access
BKB.J. Keulen
B.J. Keulen
MSM.J. Stam
M.J. Stam
MNM.G.J. de Neeling
M.G.J. de Neeling
DHD. Hubers
D. Hubers
JBJ.T. Boonstra
J.T. Boonstra
MBM. Beudel
M. Beudel

11 August 2026 in Brain Stimulation
Verified
Journal Article
Open access
YWY. Wiggerts
Y. Wiggerts
PSP.R. Schuurman
P.R. Schuurman
MSM.J. Stam
M.J. Stam
DHD. Hubers
D. Hubers
BKB.J. Keulen
B.J. Keulen
MBM. Bot
M. Bot

3 May 2026 in medRxiv
Verified
Preprint
Open access
PDF file
EREline A.M.Y. Rouleau
Eline A.M.Y. Rouleau
SGSaskia van der Gaag
Saskia van der Gaag
BKBart J. Keulen
Bart J. Keulen
MSMarije N. Scholten
Marije N. Scholten
MBMartijn Beudel
Martijn Beudel
MCM. Fiorella Contarino
M. Fiorella Contarino
Parkinson’s disease patients may experience a different therapeutic effect after replacement of the Medtronic Activa® deep brain stimulation neurostimulator with the newer Percept™ model, which features multiple independent current sources and constant-current control. We analyzed patient-reported therapeutic effect changes after Activa®-to-Percept™ replacements (AP, n=52) across six Dutch DBS-centers, comparing appropriate (AP+, n=36) and inappropriate/no (AP−, n=16) use of the manufacturer’s replacement workflow . Previous Activa®-to-Activa® replacements (AA, n=69) were used as reference. Worsened therapeutic effect was reported in 75.0% of AP−, 44.4% of AP+, and 21.7% of AA replacements (p<0.001). In the AP group, most patients with worsened effect were previously programmed with constant-voltage. Concluding, the risk of worsened therapeutic effect following AP replacements is higher compared to AA replacements, in particular when the replacement workflow is not properly used or in complex electrode configurations. We advise to use the workflow, inform the patient and plan closer follow-up appointments.